Nevertheless, our work strongly suggests that clinical interventions via targeting IL-1β may be of limited value; the cholesterol control at the very early stage of atherosclerotic changes should be a more viable method for the prevention of cardiovascular diseases. The gene discussed is IL1B; the disease is cardiovascular disorder.